NEKTAR THERAPEUTICS
NEKTAR THERAPEUTICS (NKTR): 14 pipeline candidates · ~38 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
37.5 months
D/E 0.32 · 21% dilution
Lead: Phase 3
14 candidates
N/A
0 buys · 5 sells (180d)
A transparent, data-derived signal for NEKTAR THERAPEUTICSacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.1B
Cash
$149.6M
Quarterly Burn
$44.3M
Runway
37.5 mo
Revenue
$10.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (14 candidates)
| Drug | Phase |
|---|---|
| Avelumab | Phase 2 |
| C-TIL051 | Phase 1 |
| Cetuximab | Phase 1 |
| Dapirolizumab Pegol | Phase 3 |
| Fludarabine | Phase 1 |
| M6223 | Phase 2 |
| NKTR-0165 | Phase 1 |
| nktr-0166 | Preclinical |
| NKTR-255 | Phase 1 |
| NKTR-288 | Phase 1 |
Showing 10 of 14 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
208
Total value held
$2.05B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 4,303,188 | $309.6M |
| bvf inc/il | 2,559,595 | $184.2M |
| vanguard capital management llc | 2,394,110 | $172.3M |
| two seas capital lp | 1,959,178 | $141.0M |
| two sigma investments, lp | 930,741 | $67.0M |
| susquehanna international group, llp | 903,190 | $65.0M |
| woodline partners lp | 830,670 | $59.8M |
| prosight management, lp | 735,000 | $52.9M |
| blackrock, inc. | 692,650 | $49.8M |
| citadel advisors llc | 665,431 | $47.9M |
Showing top 10 of 208 institutional holders of NEKTAR THERAPEUTICS. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in NEKTAR THERAPEUTICS's pipeline?
NEKTAR THERAPEUTICS (NKTR) has 14 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NEKTAR THERAPEUTICS's lead drug candidate?
NEKTAR THERAPEUTICS's most advanced tracked candidate is Avelumab (Phase 2) for Locally Advanced or Metastatic Urothelial Carcinoma.
What is NEKTAR THERAPEUTICS's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NEKTAR THERAPEUTICS has approximately 37.5 months of cash runway.
What is NEKTAR THERAPEUTICS's market capitalization?
NEKTAR THERAPEUTICS's market capitalization is approximately $2.1B.
Who is the CEO of NEKTAR THERAPEUTICS?
Mr. Howard W. Robin is the chief executive officer of NEKTAR THERAPEUTICS (NKTR).
Get the full picture on NEKTAR THERAPEUTICS
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.